1HB0 Stock Overview
Through its subsidiary Scorpius BioManufacturing, operates as an integrated contract development and manufacturing organization.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Scorpius Holdings, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$10.00 |
| 52 Week High | US$130.00 |
| 52 Week Low | US$10.00 |
| Beta | -0.21 |
| 11 Month Change | 0% |
| 3 Month Change | -55.75% |
| 1 Year Change | -92.06% |
| 33 Year Change | -99.05% |
| 5 Year Change | -98.76% |
| Change since IPO | -99.99% |
Recent News & Updates
Recent updates
Shareholder Returns
| 1HB0 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 0% | 0.2% | 0.7% |
| 1Y | -92.1% | -19.4% | -0.08% |
Return vs Industry: 1HB0 underperformed the German Biotechs industry which returned -19.4% over the past year.
Return vs Market: 1HB0 underperformed the German Market which returned -0.1% over the past year.
Price Volatility
| 1HB0 volatility | |
|---|---|
| 1HB0 Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 6.3% |
| Market Average Movement | 4.6% |
| 10% most volatile stocks in DE Market | 10.2% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 1HB0's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine 1HB0's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | 83 | Jeff Wolf | www.scorpiusbiologics.com |
Scorpius Holdings, Inc., through its subsidiary Scorpius BioManufacturing, operates as an integrated contract development and manufacturing organization. The company engages in clinical and commercial drug substance manufacturing; and release and stability testing activities. It is also involved in the provision of various process development services, including upstream and downstream development and optimization, and analytical method development solutions, as well as cell line development, testing, and characterization services.
Scorpius Holdings, Inc. Fundamentals Summary
| 1HB0 fundamental statistics | |
|---|---|
| Market cap | €955.71k |
| Earnings (TTM) | -€29.66m |
| Revenue (TTM) | €8.97m |
0.1x
P/S Ratio0.0x
P/E RatioIs 1HB0 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 1HB0 income statement (TTM) | |
|---|---|
| Revenue | US$9.74m |
| Cost of Revenue | US$20.78m |
| Gross Profit | -US$11.04m |
| Other Expenses | US$21.16m |
| Earnings | -US$32.20m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -65.17 |
| Gross Margin | -113.29% |
| Net Profit Margin | -330.51% |
| Debt/Equity Ratio | 8.2% |
How did 1HB0 perform over the long term?
See historical performance and comparison